[go: up one dir, main page]

PE20181071A1 - Derivados novedosos de diamino piridina - Google Patents

Derivados novedosos de diamino piridina

Info

Publication number
PE20181071A1
PE20181071A1 PE2018001004A PE2018001004A PE20181071A1 PE 20181071 A1 PE20181071 A1 PE 20181071A1 PE 2018001004 A PE2018001004 A PE 2018001004A PE 2018001004 A PE2018001004 A PE 2018001004A PE 20181071 A1 PE20181071 A1 PE 20181071A1
Authority
PE
Peru
Prior art keywords
amino
compounds
nicotinamide
chlorophenyl
refers
Prior art date
Application number
PE2018001004A
Other languages
English (en)
Inventor
Gebhard Thoma
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20181071A1 publication Critical patent/PE20181071A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE DIAMINO PIRIDINA DE FORMULA (I) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO DONDE R1 ES H O ALQUILO C1-C6; HAL ES HALOGENO TAL COMO FLUOR O CLORO. SON COMPUESTOS PREFERIDOS: 4-((2-CLOROFENIL)AMINO)-6-(PIRIDIN-2-ILAMINO)NICOTINAMIDA; 4-((2-CLOROFENIL)AMINO)-6-((6-METILPIRIDIN-2-IL)AMINO)NICOTINAMIDA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LAS QUINASAS JANUS (JAK) SIENDO UTILES PARA EL TRATAMIENTO DE DERMATITIS ATOPICA, LUPUS ERITEMATOSO SISTEMICO, ASMA
PE2018001004A 2015-11-26 2016-11-24 Derivados novedosos de diamino piridina PE20181071A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15196542 2015-11-26

Publications (1)

Publication Number Publication Date
PE20181071A1 true PE20181071A1 (es) 2018-07-04

Family

ID=54705130

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001004A PE20181071A1 (es) 2015-11-26 2016-11-24 Derivados novedosos de diamino piridina

Country Status (34)

Country Link
US (3) US10570096B2 (es)
EP (2) EP3757097B1 (es)
JP (1) JP6634157B2 (es)
KR (1) KR102097878B1 (es)
CN (2) CN112851578A (es)
AU (1) AU2016359438B2 (es)
BR (1) BR112018009540A2 (es)
CA (1) CA3005159A1 (es)
CL (1) CL2018001370A1 (es)
CO (1) CO2018005354A2 (es)
CR (1) CR20180285A (es)
CU (1) CU24506B1 (es)
CY (1) CY1123543T1 (es)
DK (1) DK3380465T3 (es)
DO (1) DOP2018000127A (es)
EA (1) EA035899B1 (es)
EC (1) ECSP18041731A (es)
ES (2) ES2829052T3 (es)
HR (1) HRP20201662T1 (es)
HU (1) HUE052345T2 (es)
IL (1) IL259360B (es)
LT (1) LT3380465T (es)
MX (1) MX379776B (es)
MY (1) MY195905A (es)
PE (1) PE20181071A1 (es)
PH (1) PH12018501019B1 (es)
PL (2) PL3757097T3 (es)
PT (2) PT3757097T (es)
RS (1) RS60946B1 (es)
RU (2) RU2020124922A (es)
SA (1) SA518391657B1 (es)
SG (1) SG11201803760VA (es)
SI (1) SI3380465T1 (es)
WO (1) WO2017089985A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3005159A1 (en) * 2015-11-26 2017-06-01 Novartis Ag Diamino pyridine derivatives
JP7222102B2 (ja) 2019-01-11 2023-02-14 ノバルティス アーゲー 化膿性汗腺炎の治療用ｌｔａ４ｈ阻害剤
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
AU2007333394C1 (en) * 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2681015C (en) 2007-03-16 2016-06-21 The Scripps Research Institute Inhibitors of focal adhesion kinase
JPWO2010058846A1 (ja) 2008-11-21 2012-04-19 アステラス製薬株式会社 ４，６−ジアミノニコチンアミド化合物
KR101361027B1 (ko) 2008-11-28 2014-02-11 코와 가부시키가이샤 피리딘-3-카르복시아미드 유도체
MX2011007750A (es) 2009-01-23 2011-09-29 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la ruta jak.
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
TW201300360A (zh) 2010-11-01 2013-01-01 Portola Pharm Inc 做為ｊａｋ激酶調節劑之菸鹼醯胺
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CA2883534A1 (en) 2012-10-19 2014-04-24 F. Hoffmann-La Roche Ag Inhibitors of syk
MX2015005272A (es) * 2012-11-08 2015-07-14 Squibb Bristol Myers Co Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa).
MA38072A1 (fr) * 2012-11-08 2016-07-29 Bristol Myers Squibb Co Composés hétérocycliques substitués par amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifn?
WO2014074675A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
JP2015014960A (ja) 2013-07-05 2015-01-22 ソニー株式会社 情報処理装置、および記憶媒体
CA2926361A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
US20180263925A1 (en) 2014-12-03 2018-09-20 Rxi Pharmaceuticals Corporation Methods for the treatment of alopecia areata utilizing gene modulation approaches
CA3005159A1 (en) * 2015-11-26 2017-06-01 Novartis Ag Diamino pyridine derivatives

Also Published As

Publication number Publication date
MY195905A (en) 2023-02-27
SG11201803760VA (en) 2018-06-28
CN108349937B (zh) 2021-02-09
MX2018006495A (es) 2018-08-15
SI3380465T1 (sl) 2020-11-30
PH12018501019B1 (en) 2023-03-15
US11274080B2 (en) 2022-03-15
EP3380465B1 (en) 2020-08-05
SA518391657B1 (ar) 2021-02-22
AU2016359438B2 (en) 2019-05-02
CR20180285A (es) 2018-07-16
PT3380465T (pt) 2020-10-23
DOP2018000127A (es) 2018-10-31
CN108349937A (zh) 2018-07-31
US20180354904A1 (en) 2018-12-13
RU2018122953A3 (es) 2020-01-29
PL3380465T3 (pl) 2021-01-25
ES2916582T3 (es) 2022-07-01
RU2730007C2 (ru) 2020-08-14
AU2016359438A1 (en) 2018-05-31
ECSP18041731A (es) 2018-06-30
KR20180067681A (ko) 2018-06-20
US20220177432A1 (en) 2022-06-09
CA3005159A1 (en) 2017-06-01
HRP20201662T1 (hr) 2020-12-25
RU2018122953A (ru) 2019-12-26
EP3380465A1 (en) 2018-10-03
LT3380465T (lt) 2020-11-10
US20200140386A1 (en) 2020-05-07
PH12018501019A1 (en) 2018-12-17
JP6634157B2 (ja) 2020-01-22
EA201891258A1 (ru) 2018-10-31
KR102097878B1 (ko) 2020-04-06
BR112018009540A2 (pt) 2018-11-06
JP2019503343A (ja) 2019-02-07
CO2018005354A2 (es) 2018-05-31
HK1253530A1 (en) 2019-06-21
HUE052345T2 (hu) 2021-04-28
PL3757097T3 (pl) 2022-07-25
RS60946B1 (sr) 2020-11-30
CN112851578A (zh) 2021-05-28
US10570096B2 (en) 2020-02-25
PT3757097T (pt) 2022-06-20
RU2020124922A (ru) 2020-08-10
IL259360A (en) 2018-07-31
CU20180044A7 (es) 2018-10-04
IL259360B (en) 2021-05-31
EA035899B1 (ru) 2020-08-28
EP3757097B1 (en) 2022-03-30
CY1123543T1 (el) 2022-03-24
CU24506B1 (es) 2021-04-07
DK3380465T3 (da) 2020-10-26
CL2018001370A1 (es) 2018-07-27
MX379776B (es) 2025-03-11
ES2829052T3 (es) 2021-05-28
WO2017089985A1 (en) 2017-06-01
EP3757097A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
CY1122500T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων
CY1121395T1 (el) Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
CY1119678T1 (el) Πυριμιδινονες ως αναστολεις τελεστη χια
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
PH12018500457A1 (en) New phenoxymethyl derivatives
CL2016002888A1 (es) Compuestos derivados de pirazolopiridinas y pirazolopirimidinas; composicion farmacéutica y su uso como inhibidores selectivos de janus quinasas (jak) en el tratamiento de enfermedades como congestion nasal, asma, epoc, rinitis alergica, diabetes entre otras.
AU2016214496B2 (en) 2-(HET)Aryl-substituted condensed bicyclic Heterocycle Derivatives as pest control agents
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
EP3331880A4 (en) N- (PYRIDIN-2-YL) -4- (THIAZOL-5-YL) PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS
PH12015502248A1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
NZ715838A (en) Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
EA201791304A1 (ru) Производные изохинолина для лечения вич
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
MX383124B (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus.
JOP20170099B1 (ar) شكل متعدد الأشكال من n-{6-(2-هيدروكسي بروبان-2-يل)-2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MY182353A (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
PH12016501613A1 (en) Pyrazines modulators of gpr6
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса
EA201992343A1 (ru) Замещенные бициклические гетероциклические соединения в качестве ингибиторов надфн-оксидазы
PE20181071A1 (es) Derivados novedosos de diamino piridina
BR112016023811A2 (pt) processo de fabricação para derivados de triazina, pirimidina e piridina